-

Advicenne: 2026 Financial Calendar

PARIS--(BUSINESS WIRE)--Regulatory News:

Advicenne (Euronext Growth Paris ALDVI - FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering from rare renal diseases, announces its 2026 financial communication calendar.

Event

Date*

2025 FY sales release

January 22, 2026

2025 FY annual financial statement

March 26, 2026

Annual General Meeting

May 21, 2026

2026 First Half financial statement

September 17, 2026

*: subject to change. End of trading

About Advicenne
Advicenne (Euronext: ALDVI) is a specialty pharmaceutical company founded in 2007, specializing in the development of innovative treatments in Nephrology. Its lead product Sibnayal® (ADV7103) has received its Marketing Approval for distal renal tubular acidosis in EU and GB. ADV7103 is currently in late-stage development in cystinuria in Europe and in dRTA and cystinuria in the US and in Canada. Headquartered in Paris, Advicenne, listed on the Euronext Paris stock exchange since 2017, has now been listed on Euronext Growth Paris since its transfer on March 30, 2022. For additional information, see: https://advicenne.com/.

Contacts

Advicenne
Didier Laurens, CEO
+33 (0)1 87 44 40 17
Email: investors@advicenne.com

Maarc
Media relations
Bruno Arabian
+33 (0)6 87 88 47 26
Email: bruno.arabian@maarc.fr

Advicenne

BOURSE:ADVIC
Release Versions
EnglishFrench

Contacts

Advicenne
Didier Laurens, CEO
+33 (0)1 87 44 40 17
Email: investors@advicenne.com

Maarc
Media relations
Bruno Arabian
+33 (0)6 87 88 47 26
Email: bruno.arabian@maarc.fr

More News From Advicenne

Advicenne Secures Its Cash Runway to Q2 2027 through a Bond Financing of a Nominal Amount of up to €3.8 Million

PARIS--(BUSINESS WIRE)--Regulatory News: Advicenne S.A. (“Advicenne” or the “Company”) (Euronext Growth Paris - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases, announced today that it has secured a two-tranche financing of a nominal amount of up to €3.8 million, through the issuance of bonds subscribed by Cemag Invest and Didier Laurens, Chairman of the Board and CEO of Advicen...

Advicenne Granted Reimbursement for Likozam® in France and Sees Thereby Its Debt Reduced by Nearly €6 Million

PARIS--(BUSINESS WIRE)--Regulatory News: Advicenne (Euronext Growth Paris - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases, announced today that Likozam® (clobazam) is reimbursed by the French social security system, notably for the combination treatment of drug-resistant epilepsy. The price of Likozam® in France, as published in the Official Journal, is: €92.24 including taxes...

Advicenne Announces Changes to Its Governance Following Its Annual General Meeting on May 21, 2026

PARIS--(BUSINESS WIRE)--Regulatory News: Advicenne (Euronext Growth Paris - FR0013296746 -ALDVI), a pharmaceutical company specializing in the development and marketing of innovativetreatments for people suffering from rare kidney diseases, announces changes to its governance following its Annual General Meeting (AGM) held on May 21, 2026. The AGM, held in Paris on May 21, 2026, adopted all the resolutions regarding the approval of the Company’s financial statements, the granting of financial d...
Back to Newsroom